|
ES2542328T3
(es)
*
|
2002-12-06 |
2015-08-04 |
Millennium Pharmaceuticals, Inc. |
Métodos para la identificación, evaluación y tratamiento de pacientes con terapia de inhibición del proteasoma
|
|
WO2005070086A2
(en)
|
2004-01-21 |
2005-08-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for determining a graft tolerant phenotype in a subject
|
|
ES2636470T3
(es)
|
2004-04-09 |
2017-10-05 |
Genomic Health, Inc. |
Marcadores de expresión génica para predecir la respuesta a la quimioterapia
|
|
EP2604703B1
(en)
|
2005-03-14 |
2017-02-01 |
The Board of Trustees of the Leland Stanford Junior University |
Methods for evaluating graft survival in a solid organ transplant recipient
|
|
USRE46843E1
(en)
|
2005-03-14 |
2018-05-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for evaluating graft survival in a solid organ transplant recipient
|
|
ES2624863T3
(es)
|
2005-06-08 |
2017-07-17 |
Millennium Pharmaceuticals, Inc. |
Métodos para identificación, evaluación, y tratamiento de pacientes con terapia de cáncer
|
|
WO2007001943A2
(en)
*
|
2005-06-20 |
2007-01-04 |
The Regents Of The University Of California |
Prefoldin 4 in the treatment and diagnosis of cancer
|
|
US8211634B2
(en)
*
|
2006-02-14 |
2012-07-03 |
Dana-Farber Cancer Institute, Inc. |
Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
|
|
JP5725711B2
(ja)
*
|
2006-08-10 |
2015-05-27 |
ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
癌治療法を有する患者の同定、評価、および治療のための方法
|
|
PL2171090T3
(pl)
*
|
2007-06-08 |
2013-09-30 |
Genentech Inc |
Markery ekspresji genów odporności guza na leczenie hamujące HER2
|
|
US9551033B2
(en)
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
|
US20080317768A1
(en)
*
|
2007-06-21 |
2008-12-25 |
Boeing Company |
Bioconjugated nanoparticles
|
|
WO2009042676A1
(en)
*
|
2007-09-24 |
2009-04-02 |
University Of South Florida |
Method for early detection of cancers
|
|
US20090099877A1
(en)
*
|
2007-10-11 |
2009-04-16 |
Hyde Roderick A |
Systems and methods for underwriting risks utilizing epigenetic information
|
|
US20090094261A1
(en)
*
|
2007-10-04 |
2009-04-09 |
Jung Edward K Y |
Systems and methods for correlating epigenetic information with disability data
|
|
US20090094065A1
(en)
*
|
2007-10-04 |
2009-04-09 |
Hyde Roderick A |
Systems and methods for underwriting risks utilizing epigenetic information
|
|
US20100027780A1
(en)
*
|
2007-10-04 |
2010-02-04 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Systems and methods for anonymizing personally identifiable information associated with epigenetic information
|
|
US20090094281A1
(en)
*
|
2007-10-04 |
2009-04-09 |
Jung Edward K Y |
Systems and methods for transferring combined epigenetic information and other information
|
|
US20090094047A1
(en)
*
|
2007-10-04 |
2009-04-09 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Systems and methods for predicting a risk utilizing epigenetic data
|
|
US20090094067A1
(en)
*
|
2007-10-04 |
2009-04-09 |
Searete LLC, a limited liability corporation of |
Systems and methods for company internal optimization utilizing epigenetic data
|
|
US20090094282A1
(en)
*
|
2007-10-04 |
2009-04-09 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Systems and methods for correlating past epigenetic information with past disability data
|
|
US20090100095A1
(en)
*
|
2007-10-04 |
2009-04-16 |
Jung Edward K Y |
Systems and methods for reinsurance utilizing epigenetic information
|
|
CN101910414B
(zh)
|
2007-11-07 |
2016-01-13 |
健泰科生物技术公司 |
用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法和组合物
|
|
EP2294215B1
(en)
*
|
2008-05-12 |
2013-01-16 |
Genomic Health, Inc. |
Tests to predict responsiveness of cancer patients to chemotherapy treatment options
|
|
WO2010021696A1
(en)
*
|
2008-08-18 |
2010-02-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for determining a graft tolerant phenotype in a subject
|
|
US7657446B1
(en)
*
|
2008-08-22 |
2010-02-02 |
Numoda Technologies, Inc. |
Automated identification of tasks that must be completed before a clinical trial database can be locked
|
|
US20120010266A1
(en)
*
|
2008-08-28 |
2012-01-12 |
Oncotherapy Science Inc., |
Tbc1d7 as tumor marker and therapeutic target for cancer
|
|
US20100169115A1
(en)
*
|
2008-12-31 |
2010-07-01 |
Tamis Robert H |
System for matching individuals with health care providers and methods thereof
|
|
ES2492498T3
(es)
|
2009-01-15 |
2014-09-09 |
The Board Of Trustees Of The Leland Stanford Junior University |
Panel de biomarcadores para el diagnóstico y la predicción de rechazo de injerto
|
|
TW201030337A
(en)
*
|
2009-02-04 |
2010-08-16 |
Tzu Chi Buddhist General Hospital |
Method and kit for detecting cancers
|
|
US20120121515A1
(en)
*
|
2009-03-13 |
2012-05-17 |
Lenny Dang |
Methods and compositions for cell-proliferation-related disorders
|
|
CN102459639A
(zh)
|
2009-04-18 |
2012-05-16 |
健泰科生物技术公司 |
用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法
|
|
TWI598337B
(zh)
|
2009-06-29 |
2017-09-11 |
阿吉歐斯製藥公司 |
治療化合物及組成物
|
|
WO2011006119A2
(en)
|
2009-07-09 |
2011-01-13 |
The Scripps Research Institute |
Gene expression profiles associated with chronic allograft nephropathy
|
|
US20120252028A1
(en)
*
|
2009-08-14 |
2012-10-04 |
Michael Shtulman |
Target genes for cancer therapy
|
|
EP2525790B1
(en)
|
2009-10-21 |
2020-05-27 |
Agios Pharmaceuticals, Inc. |
Methods and compositions for cell-proliferation-related disorders
|
|
WO2011050210A1
(en)
|
2009-10-21 |
2011-04-28 |
Agios Pharmaceuticals, Inc. |
Methods and compositions for cell-proliferation-related disorders
|
|
US9493833B1
(en)
*
|
2009-11-06 |
2016-11-15 |
The Regents Of The University Of California |
Methods for preventing induced synthesis of proteasomes in human cells
|
|
US20120231472A1
(en)
*
|
2009-11-07 |
2012-09-13 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
|
EP2507630B1
(en)
|
2009-12-02 |
2017-01-25 |
The Board of Trustees of The Leland Stanford Junior University |
Biomarkers for determining an allograft tolerant phenotype
|
|
NZ600268A
(en)
|
2010-01-11 |
2014-08-29 |
Genomic Health Inc |
Method to use gene expression to determine likelihood of clinical outcome of renal cancer
|
|
WO2011119980A1
(en)
|
2010-03-25 |
2011-09-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Protein and gene biomarkers for rejection of organ transplants
|
|
US9309435B2
(en)
|
2010-03-29 |
2016-04-12 |
The Clorox Company |
Precursor polyelectrolyte complexes compositions comprising oxidants
|
|
US20110236582A1
(en)
|
2010-03-29 |
2011-09-29 |
Scheuing David R |
Polyelectrolyte Complexes
|
|
US20130157887A1
(en)
*
|
2010-05-13 |
2013-06-20 |
Manfred Beleut |
Discrete states for use as biomarkers
|
|
IL243203A
(en)
|
2010-07-27 |
2017-04-30 |
Genomic Health Inc |
Method for using gene expression to determine prognosis of prostate cancer
|
|
WO2012024612A1
(en)
*
|
2010-08-20 |
2012-02-23 |
Pangea Biosciences, Inc. |
Cancer diagnostic and cancer therapeutic
|
|
US8962261B2
(en)
|
2011-04-06 |
2015-02-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Autoantibody biomarkers for IGA nephropathy
|
|
SMT202400081T1
(it)
|
2011-05-03 |
2024-03-13 |
Agios Pharmaceuticals Inc |
Attivatori della piruvato chinasi per uso in terapia
|
|
CN102827073A
(zh)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
治疗活性组合物和它们的使用方法
|
|
CN102827170A
(zh)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
治疗活性组合物和它们的使用方法
|
|
AU2012294493B2
(en)
|
2011-08-11 |
2017-02-23 |
Janssen Pharmaceutica Nv |
Predictors for cancer treatment
|
|
JP6238900B2
(ja)
|
2011-10-28 |
2017-11-29 |
ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
Ｎａｅ阻害物質に対する応答のバイオマーカー
|
|
CN104126017A
(zh)
*
|
2011-11-11 |
2014-10-29 |
米伦纽姆医药公司 |
对蛋白酶体抑制剂的反应的生物标记
|
|
PE20142098A1
(es)
|
2012-01-06 |
2015-01-08 |
Agios Pharmaceuticals Inc |
Compuestos terapeuticamente activos y sus metodos de uso
|
|
US9474779B2
(en)
|
2012-01-19 |
2016-10-25 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compositions and their methods of use
|
|
CA2862492A1
(en)
*
|
2012-01-24 |
2013-08-01 |
Millennium Pharmaceuticals, Inc. |
Methods of treatment of cancer
|
|
EP2812338A4
(en)
*
|
2012-01-24 |
2015-09-23 |
Millennium Pharm Inc |
METHOD FOR THE TREATMENT OF NASOPHARYNGEAL CANCER
|
|
WO2013112881A1
(en)
|
2012-01-27 |
2013-08-01 |
Thomas Jefferson University |
Mct protein inhibitor-related prognostic and therapeutic methods
|
|
DK3179393T3
(da)
|
2012-01-31 |
2020-07-27 |
Genomic Health Inc |
Genexpressionsprofilalgoritme og -test til bestemmelse af prognosen for prostatakræft
|
|
EP2906212A4
(en)
|
2012-10-15 |
2016-06-08 |
Agios Pharmaceuticals Inc |
THERAPEUTIC COMPOUNDS AND COMPOSITIONS
|
|
US12546782B2
(en)
*
|
2013-03-15 |
2026-02-10 |
Mayo Foundation For Medical Education And Research |
Identification and monitoring of monoclonal immunoglobulins related to monoclonal gammopathy by molecular mass with mass spectrometry
|
|
US10022372B2
(en)
|
2013-04-19 |
2018-07-17 |
Thomas Jefferson University |
Caveolin-1 related methods for treating glioblastoma with temozolomide
|
|
MX369911B
(es)
|
2013-05-30 |
2019-11-26 |
Genomic Health Inc |
Método basado en expresión génica para clasificar pacientes con cãncer de riñón de acuerdo al riesgo de recurrencia.
|
|
WO2015003355A2
(en)
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
|
CN105593215B
(zh)
|
2013-07-11 |
2019-01-15 |
安吉奥斯医药品有限公司 |
用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
|
|
WO2015003360A2
(en)
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
|
WO2015010297A1
(en)
|
2013-07-25 |
2015-01-29 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
|
EA038246B1
(ru)
*
|
2013-08-08 |
2021-07-29 |
Оникс Терапьютикс, Инк. |
Уровни экспрессии иммуноглобулинов в качестве биологического маркера для реакции на ингибитор протеасом
|
|
NZ723859A
(en)
|
2014-03-14 |
2023-01-27 |
Servier Lab |
Pharmaceutical compositions of therapeutically active compounds and their uses
|
|
CA2944767C
(en)
|
2014-04-04 |
2022-07-12 |
Mayo Foundation For Medical Education And Research |
Isotyping immunoglobulins using accurate molecular mass
|
|
AU2015243948B2
(en)
|
2014-04-07 |
2020-10-15 |
Minerva Biotechnologies Corporation |
Anti-NME antibody
|
|
US11104951B2
(en)
|
2014-05-22 |
2021-08-31 |
The Scripps Research Institute |
Molecular signatures for distinguishing liver transplant rejections or injuries
|
|
US10443100B2
(en)
|
2014-05-22 |
2019-10-15 |
The Scripps Research Institute |
Gene expression profiles associated with sub-clinical kidney transplant rejection
|
|
US20160018414A1
(en)
*
|
2014-07-21 |
2016-01-21 |
The Florida International University Board Of Trustees |
SAB as a Biomarker for Degenerative Diseases and Therapeutic Sensitivity in Cancers
|
|
EP3175242A4
(en)
|
2014-07-29 |
2017-12-27 |
Mayo Foundation for Medical Education and Research |
Quantifying monoclonal antibody therapeutics by lc-ms/ms
|
|
US10676792B2
(en)
*
|
2015-04-01 |
2020-06-09 |
The Regents Of The University Of California |
Prognostic and diagnostic methods for colorectal cancer
|
|
CA2989111C
(en)
|
2015-06-11 |
2023-10-03 |
Agios Pharmaceuticals, Inc. |
Methods of using pyruvate kinase activators
|
|
EP3353200A4
(en)
|
2015-09-24 |
2019-06-26 |
Mayo Foundation for Medical Education and Research |
IDENTIFICATION OF FREE LIGHT CHAINS FROM IMMOBILIZED LOBULIN BY MASS SPECTROMETRY
|
|
FI3362065T3
(fi)
|
2015-10-15 |
2024-06-19 |
Servier Lab |
Ivosidenibiä, sytarabiinia ja daunorubisiinia tai idarubisiinia käsittävä yhdistelmähoito akuutin myelooisen leukemian hoitamiseksi
|
|
KR102699521B1
(ko)
|
2015-10-15 |
2024-08-26 |
르 라보레또레 쎄르비에르 |
악성 종양의 치료를 위한 조합물 요법
|
|
WO2017085326A1
(en)
*
|
2015-11-20 |
2017-05-26 |
Universite De Strasbourg |
Method for identifying personalized therapeutic strategies for patients affected with a cancer
|
|
WO2017176630A1
(en)
*
|
2016-04-07 |
2017-10-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Noninvasive diagnostics by sequencing 5-hydroxymethylated cell-free dna
|
|
US20170298422A1
(en)
|
2016-04-18 |
2017-10-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
Simultaneous single-molecule epigenetic imaging of dna methylation and hydroxymethylation
|
|
AU2017325022B2
(en)
|
2016-09-07 |
2022-10-13 |
Mayo Foundation For Medical Education And Research |
Identification and monitoring of cleaved immunoglobulins by molecular mass
|
|
CA3048224A1
(en)
|
2016-12-23 |
2018-06-28 |
Bluefin Biomedicine, Inc. |
Anti-sez6l2 antibodies and antibody drug conjugates
|
|
EP3655553B1
(en)
*
|
2017-07-21 |
2022-03-23 |
Liquid Biopsy Research LLC |
Methods for detection of plasma cell dyscrasia
|
|
US12153052B2
(en)
|
2017-09-13 |
2024-11-26 |
Mayo Foundation For Medical Education And Research |
Identification and monitoring of immunoglobulin J chains
|
|
US11946937B2
(en)
|
2017-09-13 |
2024-04-02 |
Mayo Foundation For Medical Education And Research |
Identification and monitoring of apoptosis inhibitor of macrophage
|
|
US20190233900A1
(en)
*
|
2018-02-01 |
2019-08-01 |
Nantomics, Llc |
Biomarkers in de novo pyrimidine synthesis pathways and chemoresistance
|
|
US11013733B2
(en)
|
2018-05-16 |
2021-05-25 |
Forma Therapeutics, Inc. |
Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
|
|
US11013734B2
(en)
|
2018-05-16 |
2021-05-25 |
Forma Therapeutics, Inc. |
Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
|
|
US11311527B2
(en)
|
2018-05-16 |
2022-04-26 |
Forma Therapeutics, Inc. |
Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
|
|
US20210196701A1
(en)
|
2018-05-16 |
2021-07-01 |
Forma Therapeutics, Inc. |
Inhibiting mutant idh-1
|
|
WO2019222551A1
(en)
|
2018-05-16 |
2019-11-21 |
Forma Therapeutics, Inc. |
Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
|
|
US10769307B2
(en)
|
2018-05-30 |
2020-09-08 |
Bank Of America Corporation |
Processing system using natural language processing for performing dataset filtering and sanitization
|
|
WO2019232161A1
(en)
*
|
2018-06-01 |
2019-12-05 |
Lunella Biotech, Inc. |
Biomarkers and therapeutics for endocrine therapy resistance
|
|
US10980788B2
(en)
|
2018-06-08 |
2021-04-20 |
Agios Pharmaceuticals, Inc. |
Therapy for treating malignancies
|
|
CN109190713A
(zh)
*
|
2018-09-29 |
2019-01-11 |
王海燕 |
基于血清质谱自适应稀疏特征选择的卵巢癌微创快检技术
|
|
SG10201811119XA
(en)
*
|
2018-12-12 |
2020-07-29 |
Sengenics Sdn Bhd |
Detection of biomarkers for non-small cell lung cancer
|
|
CN109633142B
(zh)
*
|
2018-12-22 |
2021-08-27 |
中国人民解放军第四军医大学 |
一种急性髓细胞性白血病诊断模型的建立方法及其应用
|
|
US20220081727A1
(en)
*
|
2019-01-17 |
2022-03-17 |
Geninus Inc. |
Biomarker for predicting response to anticancer agent and use thereof
|
|
EP3920693A4
(en)
*
|
2019-02-04 |
2022-10-05 |
Minerva Biotechnologies Corporation |
ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS
|
|
US20220152071A1
(en)
*
|
2019-04-02 |
2022-05-19 |
Northwestern University |
Markers of efficacy of topoisomerase poisons
|
|
US20220290243A1
(en)
*
|
2019-07-01 |
2022-09-15 |
Rutgers, The State University Of New Jersey |
Identification of patients that will respond to chemotherapy
|
|
WO2021030604A1
(en)
*
|
2019-08-14 |
2021-02-18 |
University Of Massachusetts |
Urinary rna signatures in renal cell carcinoma (rcc)
|
|
WO2021108043A1
(en)
|
2019-11-27 |
2021-06-03 |
University Of Cincinnati |
Assessing treatment response with estimated number of tumor cells
|
|
RU2750103C1
(ru)
*
|
2020-02-21 |
2021-06-22 |
Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации |
Способ дифференциальной диагностики диффузных в-клеточных крупноклеточных лимфом
|
|
EP4161970A4
(en)
|
2020-06-08 |
2024-07-10 |
Minerva Biotechnologies Corporation |
ANTI-NME ANTIBODIES AND METHODS FOR TREATING CANCER OR CANCER METASTASES
|
|
CA3183682A1
(en)
|
2020-06-26 |
2021-12-30 |
Minerva Biotechnologies Corporation |
Anti-nme antibody and method of treating cancer or cancer metastasis
|
|
CN112501278A
(zh)
*
|
2020-12-03 |
2021-03-16 |
中国医学科学院病原生物学研究所 |
Smim26作为结核病诊断分子标识的用途
|
|
CN113092757B
(zh)
*
|
2021-02-23 |
2024-02-06 |
承德医学院 |
一种肺癌肝转移早期诊断试剂盒及制备使用方法
|
|
CN115372618B
(zh)
*
|
2022-09-19 |
2025-01-14 |
首都医科大学附属北京胸科医院 |
一种检测蛋白标志物水平的试剂在制备用于评估肿瘤治疗效果的诊断产品中的应用
|
|
CN116500266B
(zh)
*
|
2023-03-07 |
2025-06-17 |
南通大学附属医院 |
MRPS21基因及其RNAi干扰系统的应用
|